Cargando…

PSMA as a target for radiolabelled small molecules

Detalles Bibliográficos
Autores principales:	Eder, Matthias, Eisenhut, Michael, Babich, John, Haberkorn, Uwe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2013
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3644196/ https://www.ncbi.nlm.nih.gov/pubmed/23463331 http://dx.doi.org/10.1007/s00259-013-2374-2

Ejemplares similares

Radiolabeled PSMA Inhibitors
por: Neels, Oliver C., et al.
Publicado: (2021)

Radiation dosimetry and first therapy results with a (124)I/(131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy
por: Zechmann, Christian M., et al.
Publicado: (2014)

Radiolabeling Strategies for Tumor-Targeting Proteinaceous Drugs
por: Sugiura, Grant, et al.
Publicado: (2014)

A New Class of PSMA-617-Based Hybrid Molecules for Preoperative Imaging and Intraoperative Fluorescence Navigation of Prostate Cancer
por: Eder, Ann-Christin, et al.
Publicado: (2022)

Is nano too big?
por: Mier, Walter, et al.
Publicado: (2013)

Novel Preclinical and Radiopharmaceutical Aspects of [(68)Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer
por: Eder, Matthias, et al.
Publicado: (2014)

Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with (131)I-MIP-1095
por: Afshar-Oromieh, Ali, et al.
Publicado: (2017)

Current Status of Radiolabeled Monoclonal Antibodies Targeting PSMA for Imaging and Therapy
por: Abusalem, Mohammed, et al.
Publicado: (2023)

PSMA ligands for diagnosis and therapy of prostate cancer
por: Haberkorn, Uwe
Publicado: (2014)

Synthesis and radiolabelling of PSMA-targeted derivatives containing GYK/MVK cleavable linkers
por: Murce, Erika, et al.
Publicado: (2023)

Comparison of the radiolabeled PSMA-inhibitor (111)In-PSMA-617 and the radiolabeled GRP-R antagonist (111)In-RM2 in primary prostate cancer samples
por: Schollhammer, Romain, et al.
Publicado: (2019)

Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer
por: Afshar-Oromieh, Ali, et al.
Publicado: (2013)

Design of Internalizing PSMA-specific Glu-ureido-based Radiotherapeuticals
por: Wüstemann, Till, et al.
Publicado: (2016)

The Radiolabeling of [161Tb]-PSMA-617 by a Novel Radiolabeling Method and Preclinical Evaluation by In Vitro/In Vivo Methods
por: UYGUR, EMRE, et al.
Publicado: (2023)

The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer
por: Afshar-Oromieh, Ali, et al.
Publicado: (2014)

Design of PSMA ligands with modifications at the inhibitor part: an approach to reduce the salivary gland uptake of radiolabeled PSMA inhibitors?
por: Felber, Veronika Barbara, et al.
Publicado: (2021)

Diagnostic performance of (68)Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients
por: Afshar-Oromieh, Ali, et al.
Publicado: (2017)

Advances in PSMA theranostics
por: Jeitner, Thomas M., et al.
Publicado: (2022)

The Radiolabeled HER3 Targeting Molecules for Tumor Imaging
por: Molavipordanjani, Sajjad, et al.
Publicado: (2021)

Development and dosimetry of (203)Pb/(212)Pb-labelled PSMA ligands: bringing “the lead” into PSMA-targeted alpha therapy?
por: dos Santos, José Carlos, et al.
Publicado: (2019)

The PSMA-11-derived hybrid molecule PSMA-914 specifically identifies prostate cancer by preoperative PET/CT and intraoperative fluorescence imaging
por: Eder, Ann-Christin, et al.
Publicado: (2021)

Should Low Molecular Weight PSMA Targeted Ligands Get Bigger and Use Albumin Ligands for PSMA Targeting?
por: Huang, Steve S., et al.
Publicado: (2017)

Towards Targeted Alpha Therapy with Actinium-225: Chelators for Mild Condition Radiolabeling and Targeting PSMA—A Proof of Concept Study
por: Reissig, Falco, et al.
Publicado: (2021)

Refined Chelator Spacer Moieties Ameliorate the Pharmacokinetics of PSMA-617
por: dos Santos, José Carlos, et al.
Publicado: (2022)

Potential of Radiolabeled PSMA PET/CT or PET/MRI Diagnostic Procedures in Gliomas/Glioblastomas
por: Bertagna, Francesco, et al.
Publicado: (2020)

Radiolabeled Small Molecule Protein Kinase Inhibitors for Imaging with PET or SPECT
por: Hicks, Justin W., et al.
Publicado: (2010)

A dimerized urea-based inhibitor of the prostate-specific membrane antigen for (68)Ga-PET imaging of prostate cancer
por: Schäfer, Martin, et al.
Publicado: (2012)

E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET
por: Ceci, Francesco, et al.
Publicado: (2021)

A PSMA-targeted bispecific antibody for prostate cancer driven by a small-molecule targeting ligand
por: Lee, Sung Chang, et al.
Publicado: (2021)

Targeted alpha therapy of mCRPC: Dosimetry estimate of (213)Bismuth-PSMA-617
por: Kratochwil, Clemens, et al.
Publicado: (2017)

[(18)F]F-PSMA-1007 Radiolabelling without an On-Site Cyclotron: A Quality Issue
por: Di Iorio, Valentina, et al.
Publicado: (2021)

Optimization of Precursor Preparation in PSMA-11 Radiolabeling to Obtain a Highly Reproducible Radiochemical Yield
por: Iudicello, Antonella, et al.
Publicado: (2022)

Uptake of Prostate-Specific Membrane Antigen (PSMA) in adenoid cystic carcinoma – Is PSMA-PET-CT a helpful tool in radiation oncology?
por: König, Laila, et al.
Publicado: (2017)

Multi-curie production of gallium-68 on a biomedical cyclotron and automated radiolabelling of PSMA-11 and DOTATATE
por: Thisgaard, Helge, et al.
Publicado: (2021)

Radiolabeled Compounds for Diagnosis and Treatment of Cancer
por: Kumar, Krishan
Publicado: (2021)

(18)F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617
por: Giesel, Frederik L., et al.
Publicado: (2016)

PSMA-Targeting Radiopharmaceuticals for Prostate Cancer Therapy: Recent Developments and Future Perspectives
por: El Fakiri, Mohamed, et al.
Publicado: (2021)

Targeting of radiolabeled J591 antibody to PSMA-expressing tumors: optimization of imaging and therapy based on non-linear compartmental modeling
por: Fung, Edward K., et al.
Publicado: (2016)

2021: the year [(177)Lu]Lu-PSMA-617 RLT PSMA is ready for incorporation into clinical guidelines?: Reply to “A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands” by Dr. Germo Gericke
por: Herrmann, Ken, et al.
Publicado: (2021)

(68)Ga, (44)Sc and (177)Lu-labeled AAZTA(5)-PSMA-617: synthesis, radiolabeling, stability and cell binding compared to DOTA-PSMA-617 analogues
por: Sinnes, Jean-Philippe, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_aoc20vc9ao2mdc4uid2b5fc65g